Phosphorylated Tau

• Increased expression of the neuroplastin 65 protein is involved in neurofibrillary tangles and amyloid beta plaques in Alzheimer's disease
• The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer's disease
• Diagnostic dynamic contrast-enhanced magnetic resonance imaging blood-brain barrier assessment combined with plasma biomarkers for mild cognitive impairment
• Micro-sub regional synapse weakening by mimicking the hyperphosphorylation of microtubule associated protein Tau in dendritic spines
• miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?
• LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease
• Clinically Accurate Diagnosis of Alzheimer's Disease via Single-Molecule Bioelectronic Label-Free Profiling of Multiple Blood Extracellular Vesicle Biomarkers
• Blood-brain barrier impairment as an early marker of neurodegeneration in late-onset epilepsy of unknown origin

Characteristic accumulations of highly phosphorylated tau protein aggregates are found in several neurodegenerative tauopathies including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and some forms of frontotemporal lobar dementia (FTLD-tau). It was assumed that these pathological tau aggregates are the toxic form of tau.

see also Total Tau

see also Amyloid beta 40

see also Amyloid beta 42